<DOC>
	<DOCNO>NCT02252198</DOCNO>
	<brief_summary>Assess sensitivity specificity two nucleic acid amplification test , namely Epistem Genedrive® MolbioTruenat™ raw sputum compare WHO-endorsed GeneXpert® MTB/RIF assay use gold standard four culture</brief_summary>
	<brief_title>Evaluation Non-Inferiority Two Fast Follower Nucleic Acid Amplification Tests</brief_title>
	<detailed_description>- Estimate accuracy Epistem Genedrive® MolbioTruenat™ raw sputum sputum pellet . - Assess operational feasibility Epistem Genedrive® MolbioTruenat™ - Determine compare cost Epistem Genedrive® , MolbioTruenat™ , Xpert MTB/RIF test</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>• Clinical suspicion pulmonary TB ( include cough ≥2 week least 1 symptom typical TB ) ; Age 18 year ; Willingness study followup visit , necessary , approximately two month enrollment Willingness provide 3 sputum specimen enrollment Provision inform consent . • Receipt ≥48 cumulative hour OR three dos antiTB treatment ( define combination antiTB therapy intend treat active TB ) within 60 day prior completion sputum collection ; Inability provide inform consent ( e.g . mentally impaired ) Enrolled individual provide first sputum sample ≥ 2ml second third sputum sample ≥ 1ml classify early exclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>